Background: Recent studies show that patients with multiple nonsteroidal anti-inflammatory drug (NSAID) intolerance are frequently characterized by autoreactivity; this can be detected by autologous serum skin test (ASST). Objective: To assess whether the autologous plasma skin test (APST), a test that was recently shown to be more sensitive than ASST, may be usefully employed as a predictive test for multiple NSAID intolerance in patients with a history of single NSAID intolerance. Methods: Thirty otherwise normal adults with a history of acute urticaria following the ingestion of one single NSAID underwent an APST before being challenged with a COX-1-inhibiting NSAID other than the offending drug. Results: Sixteen patients experienced urticaria following the ingestion of the alternative NSAID and were therefore classified as multiple NSAID reactors; all 16 (100%) scored positive on APST. In contrast only 3/14 patients finally classified as single NSAID reactors were positive on APST (p < 0.001). The positive and negative predictive value of APST for multiple NSAID intolerance were 86 and 100%, respectively. Conclusion: In patients with a history of acute urticaria induced by a single NSAID APST can be usefully employed to detect patients that are prone to react to NSAID other than the original offending one.

Keywords:
Allergy, drug, Nonsteroidal anti-inflammatory drugs, Urticaria, Skin testing
1.
Stevenson DD, Sanchez-Borges M, Szczeklik A: Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001;87:177–180.
2.
Stevenson DD, Simon RA, Zuraw BL: Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs; in Adkinson NF, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER (eds): Allergy: Principles and Practice, ed 6. St Louis, Mosby, 2003, pp 1695–1710.
3.
Papa G, Romano A, Del Bono A, Quaratino D, Di Fonso M, et al: Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 1997;78:74–78.
4.
Quaratino D, Romano A, Papa G, Di Fonso M, Giuffreda F, et al: Long-term tolerability of nimesulide and acetaminophen in nonsteroidal anti-inflammatory drug-intolerant patients. Ann Allergy Asthma Immunol 1997;79:47–50.
5.
Pastorello EA, Zara C, Riario-Sforza GG, Pravettoni V, Incorvaia C: Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs. Allergy 1998;53:880–884.
6.
Nettis E, Di Paola R, Ferrannini A, Tursi A: Meloxicam in hypersensitivity to NSAID. Allergy 2001;56:803–804.
7.
Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR: Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001;87:201–204.
8.
Nettis E, Di Paola R, Napoli G, Ferrannini A, Tursi A: Benzydamine: an alternative nonsteroidal anti-inflammatory drug in patients with nimesulide-induced urticaria. Allergy 2002;57:442–445.
9.
Nettis E, Di Paola R, Ferrannini A, Tursi A: Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;88:331–334.
10.
Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R: Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002;32:397–400.
11.
Perrone MR, Artesani MC, Viola M, Gaeta F, Caringi M, Quaratino D, Romano A: Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 2003;132:82–86.
12.
Asero R: Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drug. Clin Exp Allergy 2005;35:713–716.
13.
Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW: A serological mediator in chronic idiopathic urticaria – a clinical, immunological and histological evaluation. Br J Dermatol 1986;114:583–590.
14.
Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP: Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988;90:213–217.
15.
Grattan CEH, Francis DM, Hide M, Greaves MW: Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991;21:695–704.
16.
Greaves MW: Chronic urticaria. N Engl J Med 1995;332:1767–1772.
17.
Greaves MW, O’Donnell B: Urticaria causes and treatment. Int J Immunopathol Pharmacol 1997;99:461–465.
18.
Hide M, Fancis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW: Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599–1604.
19.
Asero R, Tedeschi A, Lorini M: Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs. Ann Allergy Asthma Immunol 2002;88:468–472.
20.
Asero R, Tedeschi A, Lorini M, Caldironi G, Barocci F: Sera from patients with multiple drug allergy syndrome contain circulating histamine-releasing factors. Int Arch Allergy Immunol 2003;131:195–200.
21.
Asero R, Tedeschi A, Riboldi P, Cugno M: Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006;117:1113–1117.
22.
Asero R, Tedeschi A, Coppola R, Griffini S, Paparella P, Riboldi P, Marzano AV, Fanoni D, Cugno M: Activation of the tissue pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007;119:705–710.
23.
Schaeffer RC, Gong F, Bitrick MS, Smith TL: Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. Am J Physiol 1993;264:1798–1809.
24.
Cirino G, Cicala C, Bucci MR, Sorrentino L, Maranganore JM, Stone SR: Thrombin functions as an inflammatory mediator through activation of its receptors. J Exp Med 1996;183:821–827.
25.
Nobe K, Sone T, Paul RJ, Honda K: Thrombin-induced force development in vascular endothelial cells: contribution to alteration of permeability mediated by calcium-dependent and -independent pathways. J Pharmacol Sci 2005;99:252–263.
26.
Razin E, Marx G: Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J Immunol 1984;133:3282–3285.
27.
Vliagoftis H: Thrombin induces mast cell adhesion to fibronectin: evidence for the involvement of protease-activated receptor-1. J Immunol 2002;169:4551–4558.
28.
Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA: Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006;12:682–687.
29.
Asero R: Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. Ann Allergy Asthma Immunol 2006;97:187–189.
30.
Goldman L: Quantitative aspects of clinical reasoning; in Wilson JD, Braunwald E, Isselbacher KJ, et al. (eds): Principles of Internal Medicine. New York, McGraw-Hill, 1987, pp 5–11.
31.
Asero R, Tedeschi A, Riboldi P, Cugno M: Patients with multiple drug allergy syndrome show signs of thrombin generation similarly to patients with chronic urticaria. Ann Allergy Asthma Immunol, submitted.
32.
Asero R: Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol 2003;111:1095–1098.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.